The next generation of healthcare

We want to be in the forefront of innovation in the healthcare
industry, introducing new advanced solutions to give people a better life.
Watch the video

2010

Start

Echolight srl was officially incorporated by the founding team with a revolutionary idea: developing the first radiation-free device for early diagnosis of osteoporosis at the lumbar vertebrae and the femoral neck.

Patent

It is officially filed the first patent of R.E.M.S. technology: an innovative echographic approach for bone micro-architecture characterization.

2011

Life Science Capital

Life Science Capital S.p.a., an italian investment company in the medical device sector, invests in Echolight to support and speed up the research and development activities of the company..

EchoS

The first version of Echos is finalized: the only radiation free device for bone densitometry at the lumbar vertebrae and the femoral neck. A decisive step towards a new era in the early diagnosis of osteoporosis and bone health assessment.

2012

2013

Clinical Trials

In collaboration with the National Council of Research the first multi-center study for the clinical validation of R.E.M.S. technology in the most important reference centers for the diagnosis of osteoporosis is launched.

Certifications

Echolight secured all the standard certifications: UNI CEI EN ISO 13485: 2012, ISO 13485: 2003, UNI EN ISO 9001: 2008 Quality Management System and the CE mark for Echos, EchoStation and EchoStudio by KIWA CERMET.

2014

2015

Premiere

Echolight introduces to the international medical community the latest release of Echos at the World Congress of Osteoporosis.

Investment Round

Panakès and Invitalia Ventures have co-led an investment round in Echolight, in order to support the clinical validation of the innovative technology and the worldwide launch of the product.

2016

Scientific Advisory Board

Echolight established the new international scientific advisory board with the most important medical personalities in the diagnosis of osteoporosis.

2017

Market Launch

Echolight at the International Trade Fair MEDICA launched Echos after extensive research and development activities carried out over the last eight years.

FDA Clearence

Echolight S.p.A. has received 510(k) clearance from the Food and Drug Administration (FDA) to market its range of products in the U.S.A.

2018

Multicenter Publication

Milestone pubblication on Osteoporosis International about R.E.M.S. Multicenter Clinical Trial: “Radiofrequency echographic multispectrometry compared with dual X-ray absorptiometry for osteoporosis diagnosis on lumbar spine and femoral neck.”

Consensus Paper

Echolight obtained a Consensus Paper from ESCEO (European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, on R.E.M.S. technology.

2019

Worldwide sales network

Echolight in less than three years has a sales network of 40 distributors and several hundred satisfied customers all over the world.”

Imagination. Knowledge. Innovation.

We secured all the standard certifications: UNI CEI EN ISO 13485: 2016,
UNI EN ISO 9001: 2015 Quality Management System, CE Mark, FDA Clearence
and other main certifications all over the world for our innovative solutions.
The products

Research & Dreams

In collaboration with the National Council of Research, we carried out
international multi-center studies for the clinical validation of the proprietary
technology in the most important reference centers for the diagnosis of osteoporosis
under the lead of our prestigious scientific advisory board.

The technology

International scientific advisory board

Around the globe

Echolight, a growing med-tech company located in Italy,
in less than three years has a sales network of 40 distributors
and several hundred satisfied customers all over the world.

Become distributor